2. Search Result
Search Result
Results for "

Sprague-Dawley rat

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

1

Biochemical Assay Reagents

8

Peptides

1

Inhibitory Antibodies

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-E70558
    5α-reductase, Rat(Sprague-Dawley) Liver

    		5 alpha Reductase Endocrinology
    5α-reductase, Rat(Sprague-Dawley) Liver is the enzyme responsible for the conversion of testosterone into 5-alpha dihydrotestosterone (DHT), which is a potent androgen involved in male sexual differentiation.5α-reductase enzyme family is comprised of 3 subfamilies and 5 isoenzyme members: 5αR1, 5αR2, 5αR3, GPSN2, and GPSN2L .
    5α-reductase, Rat(Sprague-Dawley) Liver
  • HY-W102714
    1,2-Cyclohexylenedinitrilotetraacetic acid

    CDTA

    		 Biochemical Assay Reagents Neurological Disease
    1,2-Cyclohexylenedinitrilotetraacetic acid (CDTA) is a chelating agent. 1,2-Cyclohexylenedinitrilotetraacetic acid has an ability to remove manganese from brain and liver (in vivo) and their sub-cellular fractions (in vitro), of rats pretreated with manganese sulphate .
    1,2-Cyclohexylenedinitrilotetraacetic acid
  • HY-127125
    Diclofenac ethyl ester

    		COX Inflammation/Immunology
    Diclofenac ethyl ester is the prodrug of Diclofenac (HY-15036), that is encapsulated in polymer micelles in vitro, and released with prolonged circulation time and reduced drug concentrations in the heart and kidneys in vivo .
    Diclofenac ethyl ester
  • HY-121123
    Adamantanine

    2-Aminoadamantane-2-carboxylic acid

    		 Aminopeptidase Cancer
    Adamantanine (2-Aminoadamantane-2-carboxylic acid) inhibits the transport of methionine (Ki is 0.76 mM) and leucine into Ehrlich ascites carcinoma cells. Adamantanine inhibits proliferation of P388 lymphocytic leukemia cells with an IC50 of >1 mM. Adamantanine inhibits the leucine aminopeptidase with an I/S0.5 of 10.5 .
    Adamantanine
  • HY-E70558A
    5α-reductase, Rat(Sprague-Dawley) Testis

    		5 alpha Reductase Endocrinology
    5α-Reductase, Rat (Sprague-Dawley) Testis is the enzyme responsible for the conversion of testosterone into 5-alpha dihydrotestosterone (DHT), which is a potent androgen involved in male sexual differentiation.5α-reductase enzyme family is comprised of 3 subfamilies and 5 isoenzyme members: 5αR1, 5αR2, 5αR3, GPSN2, and GPSN2L .
    5α-reductase, Rat(Sprague-Dawley) Testis
  • HY-N11925
    (+)-Osbeckic acid

    		Others Cardiovascular Disease
    (+)-Osbeckic acid is a vasorelaxatant that can be isolated from Tartary Buckwheat. (+)-Osbeckic acid has a potent vasorelaxant effect in Sprague-Dawley rat thoracic aorta rings with an EC50 of 887 μM .
    (+)-Osbeckic acid
  • HY-P5130
    Big endothelin-1 (rat 1-39)

    		Endothelin Receptor Cardiovascular Disease
    Big endothelin-1 (rat 1-39) is a 39-residues peptide. Big endothelin-1 (rat 1-39) induces diuretic and natriuretic response in conscious Sprague-Dawley rats. Big endothelin-1 (rat 1-39) raises blood pressure in mice .
    Big endothelin-1 (rat 1-39)
  • HY-151360
    NHE3-IN-3

    		Sodium Channel Metabolic Disease
    NHE3-IN-3 (Compound 1) is a Na +/H + exchanger isoform 3 (NHE3) inhibitor with pIC50 of 6.2 and 6.6 against human and rat NHE3, respectively. NHE3-IN-3 shows high (98%) oral bioavailability in Sprague–Dawley rats .
    NHE3-IN-3
  • HY-N2196
    Ajugasterone C

    		Others Inflammation/Immunology
    Ajugasterone C is an ecdysteroid isolated from Leuzea carthamoides. Ajugasterone C shows significant inhibitory effect at 100 mg/kg dose on rat paw oedema development due to Carrageenan-induced inflammation in Sprague Dawley rats .
    Ajugasterone C
  • HY-117443
    IWP-051

    		Guanylate Cyclase Cardiovascular Disease
    IWP-051 is an agonist for soluble guanylate cyclase with an EC50 of 290 nM. IWP-051 stimulates the generation of cGMP, and exhibits the synergistic effect with NO. IWP-051 exhibits good pharmacokinetic characteristics in rats .
    IWP-051
  • HY-10704
    PTP1B-IN-1
    5 Publications Verification

    PTP1B inhibitor

    		 Phosphatase NF-κB Neurological Disease Inflammation/Immunology
    PTP1B-IN-1 (Compound 7a) is a small molecule inhibitor of PTP1B with an IC50 value of 1.6 mM. It is often used as the mother core for derivatives of analogues .
    PTP1B-IN-1
  • HY-172147
    SSTR4 agonist 5

    		Somatostatin Receptor Neurological Disease
    SSTR4 agonist 5 (Compound 5) is the orally active agonist for somatostatin receptor 4 (SSTR4) with an EC50 of 0.228 nM. SSTR4 agonist 5 exhibits good stability in human/rat liver microsomes. SSTR4 agonist 5 inhibits mechanical hyperalgesia in rat models .
    SSTR4 agonist 5
  • HY-169963
    PDE1-IN-8

    		Phosphodiesterase (PDE) Others
    PDE1-IN-8 (Compound 3f) is the inhibitor for PDE1 with an IC50 of 11 nM. PDE1-IN-8 inhibits cAMP and cGMP signaling pathway, inhibits the differentiation and proliferation of cells into myofibroblast, and exhibits anti-fibrotic efficacy in Bleomycin (HY-17565)-induced rat pulmonary fibrosis model .
    PDE1-IN-8
  • HY-P5875A
    P4pal10 TFA

    		Protease Activated Receptor (PAR) Cardiovascular Disease Inflammation/Immunology
    P4pal10 TFA is the TFA salt form of P4pal10 (HY-P5875). P4pal10 TFA is an antagonist for protease-activated receptor 4 (PAR4). P4pal10 TFA inhibits the platelet aggregation, inhibits tissue factor (TF)-induced thrombin generation, and exhibits anticoagulant and antithrombotic activities. P4pal10 TFA reduces the oedema and the granulocyte infiltration induced by Carrageenan (HY-125474). P4pal10 TFA ameliorates the injury in rats myocardial ischemia/reperfusion (I/R) models .
    P4pal10 TFA
  • HY-N13714
    O-Methylcassythine

    		Endogenous Metabolite Cardiovascular Disease
    O-Methylcassythine is an aporphine alkaloid, that can be isolated from Cassytha filiformis. O-Methylcassythine exhibits vasodilator activity .
    O-Methylcassythine
  • HY-N0730
    Diosgenin glucoside

    		Autophagy Apoptosis Neurological Disease Inflammation/Immunology
    Diosgenin glucoside, a saponin compound extracted from Trillium tschonoskii, provides neuroprotection by regulating microglial M1 polarization. Diosgenin glucoside protects against spinal cord injury by regulating autophagy and alleviating apoptosis .
    Diosgenin glucoside
  • HY-50692
    CAY10734

    		LPL Receptor Inflammation/Immunology
    CAY10734 is the agonist for sphingosine-1-phosphate receptor 1 (S1P1) with an IC50 of 1.3 nM. CAY10734 promotes the recirculation of peripheral blood lymphocytes, and is a potential immunosuppressant .
    CAY10734
  • HY-P1134
    Galanin (1-15) (porcine, rat)

    		5-HT Receptor Neurological Disease
    Galanin (1-15) (porcine, rat) is the N-terminal 15 amino acids peptide fragment of the neuropeptide galanin. Galanin (1-15) (porcine, rat) interacts with the 5-HT1A receptor in the dorsal hippocampus of the rat brain, reduces the affinity of 5-HT1A receptors, and regulates the serotonin neuronal networks .
    Galanin (1-15) (porcine, rat)
  • HY-169986S
    TyK2-IN-21-d3

    		JAK Inflammation/Immunology
    TyK2-IN-21-d3 (Compound 3c) is the orally active prodrug of the tyrosine kinase 2. TyK2-IN-21-d3 exhibits good chemical stability in aqueous system under different pHs. TyK2-IN-21-d3 alleviates the effect of gastric acid changes on drug absorption and improve the drug bioavailability in rat model .
    TyK2-IN-21-d3
  • HY-113093
    Ethyl glucuronide

    		Endogenous Metabolite Toll-like Receptor (TLR) Neurological Disease
    Ethyl glucuronide is an endogenous metabolite. Ethyl glucuronide is the metabolite of ethanol. Ethyl glucuronide is a biomarker for ethanol exposure that accumulates in hair and reflects the alcohol intake over a time period. Ethyl glucuronide is the agonist for TLR4 .
    Ethyl glucuronide
  • HY-120287
    L-054522

    		Somatostatin Receptor Endocrinology
    L-054522 is an agonist for somatostatin receptor subtype 2 with Kd of 0.01 nM. L-054522 inhibits growth hormone release from rat primary pituitary cell (IC50=0.05 nM) and glucagon and insulin release from isolated mouse pancreatic islet cell (IC50=0.05 nM and 12 nM) .
    L-054522
  • HY-159062
    Goji Extract

    		Biochemical Assay Reagents NO Synthase Neurological Disease
    Goji Extract is a natural product with anti-aging, antioxidant, and neuroprotective effects. The antioxidant effect of Goji Extract has a positive impact on erectile dysfunction and can be used in research to improve erectile function .
    Goji Extract
  • HY-P10767
    MD01-67

    		Neurotensin Receptor Neurological Disease
    MD01-67 is a selective macrocyclic compound targeting the neurotensin receptor type 2 (NTS2), with Ki of 2.9 nM. MD01-67 exhibits analgesic and tactile hypersensitivity reducing activity in rats acute/persistent/chronic inflammatory pain models .
    MD01-67
  • HY-163998
    TLR4-IN-1

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR4-IN-1 (compound 3k) inhibits the cell viability of RAW264.7 with an IC50 of 1.02 μM. TLR4-IN-1 inhibits the release of cytokine TNF-α, IL-1β and IL-6, and exhibits anti-inflammatory efficacy in rats rheumatoid arthritis models .
    TLR4-IN-1
  • HY-161784
    GABAA receptor modulator-5

    		GABA Receptor Neurological Disease
    GABAA receptor modulator-5 (Compound S28) is a modulator for (γ-aminobutyric acid)A receptor (GABAA receptor), with EC50 of 56 nM and 10 nM, for α1β2γ2 and α4β3δ subtype. GABAA receptor modulator-5 exhibits good pharmacokinetic characteristics in rats. GABAA receptor modulator-5 is slightly toxic toxicity in rats with a loss of rollover reflex (LORR) threshold dose of 23.3 μmol/kg, and exhibits potential ameliorating the postpartum depression .
    GABAA receptor modulator-5
  • HY-W931056
    AMG-628

    		TRP Channel Neurological Disease
    AMG-628 is an orally active inhibitor for TRPV1, that inhibits Capsaicin (HY-10448) or acid (pH 5)-induced Ca 2+ influx into TRPV1- expressing CHO cell with IC50 of 4.9 and 3.1 nM. AMG-628 exhibits analgesic activity in Capsaicin (HY-10448)-induced rat model, and exhibits a half-life of 2.4 h in rats .
    AMG-628
  • HY-168333
    5-HT6 inverse agonist 1

    		5-HT Receptor mTOR CDK Neurological Disease
    5-HT6 inverse agonist 1 (Compound 33) is an antagonist for 5-HT6 receptor with a Ki of 23 nM and a Kb of 6.62 nM. 5-HT6 inverse agonist 1 inhibits the 5-HT6R mediated Cdk5 and mTOR signaling pathway. 5-HT6 inverse agonist 1 reduces tactile hypersensitivity in spinal nerve ligation (SNL)-induced rat model .
    5-HT6 inverse agonist 1
  • HY-B1573A
    (±)-Butaclamol hydrochloride

    AY-23,028; dl-Butaclamol hydrochloride

    		 Adrenergic Receptor Dopamine Receptor Neurological Disease
    (±)-Butaclamol hydrochloride (AY-23,028) is the antagonist for adrenergic receptor and dopamine receptor. (±)-Butaclamol hydrochloride antagonizes amphetamine or Apomorphine (HY-12723)-induced stereotyped behaviors and emesis, inhibits discriminative avoidance behavior, and induces catalepsy in rats models .
    (±)-Butaclamol hydrochloride
  • HY-161925
    sTGFBR3 antagonist 1

    		TGF-β Receptor Neurological Disease Inflammation/Immunology
    sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC50 of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research .
    sTGFBR3 antagonist 1
  • HY-B1258
    4-(Aminomethyl)benzoic acid

    Aminomethylbenzoic acid; α-Amino-p-toluic acid

    		 Amino Acid Derivatives Cancer
    4-(Aminomethyl)benzoic acid is a competitive inhibitor of PepT1 and has antifibrinolytic activity .
    4-(Aminomethyl)benzoic acid
  • HY-162963
    PPARδ agonist 11

    		PPAR Inflammation/Immunology
    PPARδ agonist 11 (Compound 11) is a selective agonist for PPARδ with an EC50 of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema .
    PPARδ agonist 11
  • HY-B1059
    Levosulpiride

    RV-12309; S-(-)-Sulpiride

    		 Dopamine Receptor 5-HT Receptor Neurological Disease Metabolic Disease
    Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic agent of the benzamide class.
    Levosulpiride
  • HY-168068
    Res-Glu3

    		Others Neurological Disease
    Res-Glu3 is the derivative of Resveratrol (HY-16561). Res-Glu3 mitigates the ROS accumulation, and exhibits neuroprotective efficacy against H2O2-caused cellular damage in PC12. Res-Glu3 exhibits antioxidant activity in rats ischemia reperfusion models .
    Res-Glu3
  • HY-128749
    D-Glucaric acid potassium

    Potassium D-glucarate

    		 Endogenous Metabolite Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    D-Glucaric acid potassium (Potassium D-glucarate) is an orally active end product of the D-glucuronic acid pathway in mammals. D-Glucaric acid potassium is present in a variety of fruits and vegetables. D-Glucaric acid potassium has cholesterol-lowering and anti-tumor activities. D-Glucaric acid potassium can inhibit tumor cell proliferation and inflammation, and induce apoptosis .
    D-Glucaric acid potassium
  • HY-170586
    JAK05

    		Bacterial Na+/K+ ATPase COX TNF Receptor Prostaglandin Receptor Infection Inflammation/Immunology
    JAK05 exhibits inhibitory activity against Helicobacter pylori, inhibits strains J63, J196 and J107 with MIC of 3-5 µg/mL. JAK05 exhibits binding affinity to H+/K+-ATPase, COX-1/2, TNF-α and PGE2, reveals antioxidant and anti-inflammatory activities. JAK05 exhibits anti-ulcer activity in rat ethanol-induced gastric ulcer models .
    JAK05
  • HY-10716A
    PF-03463275

    		GlyT Neurological Disease
    PF-03463275 is a centrally penetrant, orally available, selective, and competitive GlyT1 (glycine transporter-1) reversible inhibitor, with a Ki of 11.6 nM. PF-03463275 has the potential for Schizophrenia research .
    PF-03463275
  • HY-164040
    Zavolosotine

    		Somatostatin Receptor Metabolic Disease
    Zavolosotine (Compound 1) is an orally active agonist for somatostatin receptor type 5 (SST5) with EC50 <1 nM. Zavolosotine inhibits insulin and glucagon secretion, increases levels of glucagon in blood in rat model .
    Zavolosotine
  • HY-160023
    Elisrasib

    D3S-001

    		 Ras Cancer
    Elisrasib is an orally active inhibitor for KRAS. Elisrasib inhibits the proliferation of KRAS G12C mutant H358 and MIA-PA-CA-2 with an IC50 of 0.6 and 0.44 nM. Elisrasib exhibits good metabolic stability in hepatocytes, liver microsomes, plasma and whole blood in various species. D3S-001 exhibits good pharmacokinetic characteristics and antitumor efficacy in mice .
    Elisrasib
  • HY-151066
    BMS-1233

    		PD-1/PD-L1 Cancer
    BMS-1233 is an orally active inhibitor for programmed cell death-ligand 1 (PD-L1), with IC50 of 14.5 nM. BMS-1233 promotes cell death of HepG2 in a Jurkat T cell and HepG2 cell co-culture model, exhibits antitumor activity against melanoma in mouse model .
    BMS-1233
  • HY-164320
    Anticancer agent 245

    		Others Cancer
    Anticancer agent 245 (Compound 115) inhibits proliferation of cancer cell SKOV3, MDA-MB-231 and HCT-116 with IC50 of 0.021, 0.056 and 0.11 μM, respectively. Anticancer agent 245 exhibits antitumor efficacy in mice and good pharmacokinetic characteristics in rat models .
    Anticancer agent 245
  • HY-160959
    AN317

    		nAChR Neurological Disease
    AN317 is a selective agonist for α6β2-containing nicotinic acetylcholine receptor (nAChR) with Ki of 6.2 nM and 4.1 nM, for α6/α3β2β3 receptor and α4β2 receptor, respectively. AN317 induces dopamine release in the synaptosomes of the rat striatum, enhances dopaminergic neuronal activity in substantia nigra, and exhibits protective efficacy to rat neurons against dopamine neurotoxin MPP +. AN317 exhibits good pharmacokinetic characteristics in rats. AN317 penetrates the blood-brain barrier (BB) .
    AN317
  • HY-75368
    SRI-31255

    		LRRK2 Neurological Disease
    SRI-31255 is an orally active LRRK2 inhibitor with IC50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by binding to the ATP-binding pocket of LRRK2, inhibiting kinase activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease .
    SRI-31255
  • HY-19590
    Etarotene

    Ro 15-1570

    		 Drug Derivative Cancer
    Etarotene (Ro 15-1570) is a derivative of Arotinoid (HY-106735). Etarotene is an orally active antitumor agent against DMBA (HY-W011845)-induced mammary tumor and causes toxic symptoms of hypervitaminosis A in rat model .
    Etarotene
  • HY-120476
    JNJ-39729209

    		TRP Channel Neurological Disease Inflammation/Immunology
    JNJ-39729209 is an antagonist for transient receptor potential vanilloid 1 (TRPV1) with pIC50 of 7.9, 8.5, 7.9 and 7.7 for TRPV1 from human, rat, canine and guinea pig. JNJ-39729209 inhibits Capsaicin (HY-10448)-induced hypotension and inhibit thereby hypothermia. JNJ-39729209 exhibits anti-inflammatory and analgesic activities in Carrageenan (HY-125474)- and CFA (HY-153808)-induced thermal hyperalgesia rat models. JNJ-39729209 exhibits anti-cough effects in guinea pigs .
    JNJ-39729209
  • HY-172200
    PD-L1/HDAC6-IN-1

    		PD-1/PD-L1 HDAC Cancer
    PD-L1/HDAC6-IN-1 (Compound HP29) is the inhibitor for PD-L1 and HDAC6 that inhibits the PD-L1/PD-1 interaction and HDAC6 with an IC50 of 26.8 nM and 69 nM. PD-L1/HDAC6-IN-1 enhances the killing ability of Jurkat T cells against HepG2 cells with an IC50 of 3.4 μM. PD-L1/HDAC6-IN-1 exhibits good pharmacokinetics characteristics in rats with a drug exposure of 871.62 ng·h/mL, and exhibits antitumor activity in mouse B16-F10 xenograft models .
    PD-L1/HDAC6-IN-1
  • HY-169177
    JNK-1-IN-4

    		JNK Inflammation/Immunology
    JNK-1-IN-4 (Compound E1) is an inhibitor for JNK, that inhibits JNK-1, JNK-2 and JNK-3 with IC50s of 2.7, 19.0 and 9.0 nM, respectively. JNK-1-IN-4 inhibits the phosphorylation of c-Jun, and reduces the expression of TGF-β1-induced EMT marker proteins, such as fibronectin and α-SMA. JNK-1-IN-4 exhibits good pharmacokinetic characteristics with a bioavailability of 69%. JNK-1-IN-4 exhibits anti-fibrotic effect in Bleomycin (HY-17565)-induced mice idiopathic pulmonary fibrosis models .
    JNK-1-IN-4
  • HY-P10587
    Icotrokinra

    JNJ-77242113; JNJ-2113; PN-235

    		 Interleukin Related STAT Inflammation/Immunology
    Icotrokinra (JNJ-77242113) is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. In addition, Icotrokinra exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease .
    Icotrokinra
  • HY-161705
    Anti-apoptotic agent 1

    		Apoptosis Neurological Disease
    Anti-apoptotic agent 1 (Compound B4) exhibits neuroprotective activity and good pharmacokinetic properties. Anti-apoptotic agent 1 inhibits apoptosis, prevents stroke recurrence in photothrombotic rat model .
    Anti-apoptotic agent 1
  • HY-P3641A
    Kisspeptin 13 TFA

    		GnRH Receptor Neurological Disease Metabolic Disease
    Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC50 of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .
    Kisspeptin 13 TFA
  • HY-164010
    SUN-1334H free base

    		Histamine Receptor Dopamine Receptor Adrenergic Receptor Sigma Receptor Cardiovascular Disease Inflammation/Immunology
    SUN-1334H free base is an orally active inhibitor for histamine H1 receptor, with an IC50 of 20.3 nM and Ki of 9.7 nM. SUN-1334H free base inhibits histamine-induced contractions of isolated guinea-pig ileum with an IC50 of 0.198 μM. SUN-1334H free base inhibits histamine-induced bronchoconstriction in guinea pigs, histamine-induced skin wheals in beagle dogs, and ovalbumin-induced rhinitis in guinea pigs .
    SUN-1334H free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: